CDK6 and acute myeloid leukemia: PBMCs from patients which responded to the combination EGT for high risk MDS or AML demonstrated in vitro significant induction of miR-124 and inhibition of CDK4 and CDK6 (and a trend to inhibit EZH2) mRNA expression.